Newsroom

Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day

TAKEDA ANNOUNCES LAUNCH OF EXCHANGE OFFER FOR ANY AND ALL OF ITS $1.250 BILLION 4.000% SENIOR NOTES DUE 2021, $1.500 BILLION 4.400% SENIOR NOTES DUE 2023 AND $1.750 BILLION 5.000% SENIOR NOTES DUE 2028

New Analyses from the Phase 3 HELP Study^™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO^® (lanadelumab-flyo) Injection During Extended Study Treatment Period

Phase 3 Trial of NINLARO^TM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation

Takeda’s Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure